+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Neamine is preferential as an anti-prostate cancer reagent by inhibiting cell proliferation and angiogenesis, with lower toxicity than cis-platinum



Neamine is preferential as an anti-prostate cancer reagent by inhibiting cell proliferation and angiogenesis, with lower toxicity than cis-platinum



Oncology Letters 10(1): 137-142



Hormone therapy is the most commonly used treatment for prostate cancer, but for androgen-independent cancer, few effective treatment methods are available. Therefore, the requirement to develop novel and effective anti-prostate cancer drugs is extremely urgent. Angiogenin has been suggested as a molecular target for prostate cancer treatment; its overexpression contributes to androgen-dependent prostate cancer growth and castration-resistant growth of androgen-independent prostate cancer. The aim of the present study was to investigate whether neamine, a low toxicity angiogenin nuclear translocation inhibitor, has preferential anti-prostate cancer activity compared with cis-platinum (DDP) and the mechanisms involved. Immunofluorescence and MTT assays were used to observe the effect of neamine on the nuclear translocation of angiogenin and cell proliferation, and a PC-3 cell transplanted tumor model was used to investigate the in vivo activity of neamine and DDP. Immunohistochemistry was performed to observe the expression of angiogenin, cluster of differentiation (CD)31 and Ki-67. It was found that neamine blocked nuclear translocation of angiogenin effectively and inhibited angiogenin-induced human umbilical vein endothelial cell and PC-3 cell proliferation in a dose-dependent manner. Neamine exerted a comparative antitumor effect, but lower toxicity (weight loss), in the PC-3 xenograft models treated with DDP. Neamine consistently reduced the expression of angiogenin and CD31 significantly, but no difference was found in Ki-67 expression compared with DDP. These data suggested that neamine may be a promising agent for prostate cancer treatment.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058382472

Download citation: RISBibTeXText

PMID: 26170989

DOI: 10.3892/ol.2015.3227


Related references

Neamine inhibits oral cancer progression by suppressing angiogenin-mediated angiogenesis and cancer cell proliferation. Anticancer Research 34(5): 2113-2121, 2014

A novel FGFR1-binding peptide exhibits anti-tumor effect on lung cancer by inhibiting proliferation and angiogenesis. International Journal of Biological Sciences 14(10): 1389-1398, 2018

Effect of inhibiting tumor angiogenesis on cell proliferation and apoptosis in mice with bladder cancer. Journal of China Medical University 32(2): 148-150, 2003

Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Research 68(6): 2043-2050, 2008

Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers. Official Gazette of the United States Patent & Trademark Office Patents 1260(1), 2002

Terbinafine inhibits oral squamous cell carcinoma growth through anti-cancer cell proliferation and anti-angiogenesis. Molecular Carcinogenesis 51(5): 389-399, 2012

RRS1 silencing suppresses colorectal cancer cell proliferation and tumorigenesis by inhibiting G2/M progression and angiogenesis. Oncotarget 8(47): 82968-82980, 2017

Peroxisome proliferator-activated receptor-gamma agonists impede tumor growth in non-small cell lung cancer by inhibiting cell proliferation and angiogenesis. Proceedings of the American Association for Cancer Research Annual Meeting 44: 466, 2003

A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proceedings of the National Academy of Sciences of the United States of America 103(39): 14519-14524, 2006

Sub-chronic 90-day toxicity of neamine in SD rats and its anti-liver cancer activity in vitro and in vivo. Toxicology and Applied Pharmacology 315: 50-59, 2017

Prostate cancer cell proliferation and angiogenesis in different obese mice models. International Journal of Experimental Pathology 91(4): 374-386, 2010

Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis. Cancer Science 103(6): 1090-1098, 2012

MiR-141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression. Biochemical and Biophysical Research Communications 482(4): 1381-1386, 2017

MicroRNA-302a Suppresses Tumor Cell Proliferation by Inhibiting AKT in Prostate Cancer. Plos one 10(4): E0124410, 2015

Ubenimex inhibits cell proliferation, migration and invasion by inhibiting the expression of APN and inducing autophagic cell death in prostate cancer cells. Oncology Reports 35(4): 2121-2130, 2016